What is Gentronix?
Gentronix operates as a specialized Contract Research Organization (CRO) dedicated to delivering predictive toxicology products and services. With over a quarter-century of expertise, the company offers a comprehensive suite of genotoxicity testing solutions, encompassing both regulatory studies and innovative screening assays. Gentronix serves a diverse clientele, including companies requiring early-stage screening and robust regulatory safety assessments for their chemical products. Their commitment lies in providing high-quality scientific data to assist clients in navigating the intricate landscape of toxicology regulations.
How much funding has Gentronix raised?
Gentronix has raised a total of $939K across 1 funding round:
Unspecified
$939K
Unspecified (2021): $939K with participation from Mercia Group
Key Investors in Gentronix
Mercia Group
Mercia Group Ltd is an entity that provides comprehensive training and support services, particularly for accountants, focusing on regulatory training and skills development. Their involvement suggests a strategic interest in companies that require rigorous compliance and safety assessments.
What's next for Gentronix?
The recent major strategic investment positions Gentronix for accelerated growth and enhanced service offerings in the critical field of chemical safety assessment. This capital infusion is expected to fuel advancements in their predictive toxicology technologies and expand their market reach. As a specialist CRO with a strong track record, Gentronix is poised to further solidify its leadership in supporting the global chemical industry's compliance and safety initiatives, potentially leading to further enterprise-level funding rounds as they scale their operations and impact.
See full Gentronix company page
